Modeling and Analyses to Identify Potential Dosing Regimens of DX-2930 for the Long-Term Prophylaxis of Hereditary Angioedema

In the Phase 1b study, at 27,000 ng/mL (corresponding to approximate drug levels at Day 22 for 300 mg DX-2930), 2-chain high-molecular-weight kininogen was suppressed to a level approximating that observed in healthy subjects.

Saved in:
Bibliographic Details
Published in:Journal of allergy and clinical immunology 2016-02, Vol.137 (2), p.AB252-AB252
Main Authors: Wedner, H. James, MD FAAAAI, Busse, Paula J., MD FAAAAI, Banerji, Aleena, MD, Shennak, Mustafa, Lumry, William R., MD FAAAAI, Davis-Lorton, Mark A., MD FAAAAI, Jacobs, Joshua S., MD, Baker, James W., MD FAAAAI, Bernstein, Jonathan A., MD, Lockey, Richard F., MD, Li, H. Henry, MD PhD, Craig, Timothy J, Cicardi, Marco, Riedl, Marc A., MD MS, Al-Ghazawi, Ahmad, Soo, Carolyn, Iarrobino, Ryan, Sexton, Daniel, TenHoor, Christopher, Faucette, Ryan, Biedenkapp, Joseph C, Chyung, Yung H, Adelman, Burt
Format: Article
Language:English
Subjects:
Allergy and Immunology
Drug dosages
HIV
Human immunodeficiency virus
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In the Phase 1b study, at 27,000 ng/mL (corresponding to approximate drug levels at Day 22 for 300 mg DX-2930), 2-chain high-molecular-weight kininogen was suppressed to a level approximating that observed in healthy subjects.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2015.12.909